Mar 20, 2020
Comprising less than 1% of all the adult malignancies, and inflicting pain in more than one body organ, the rarity and heterogeneity of sarcomas make it difficult to diagnose, treat and run a clinical trial resulting in efficient outcomes. The reason, why Soft tissue sarcoma market (STS market) has limited treatmen...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper